March 23, 2023
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer(Securities Code: 4582)

Notice of Appointments to the Board of Directors and substitute member of the Audit &Supervisory Committee, and Appointments of Corporate Officers
TOKYO, Japan, March 23, 2023 - SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today
announced appointments to its Board of Directors and one substitute member of the Audit &Supervisory Committee made by resolution of shareholders approved at the 18th Annual General
Meeting of Shareholders (the “AGM”), and Representative Director and Corporate Officer appointments
approved by the Board of Directors at a board meeting convened following the close of the AGM. The
appointments are as follows:
1.

Members of the Board of Directors (excluding directors who are Audit and Supervisory Committee
members)
Name

2.

Fuminori Yoshida

Representative Director

Shigetoshi Matsumoto
Bruce David Cheson
Eiji Ebinuma

Board Director <Outside>
Board Director <Outside>
Board Director <Outside>

Substitute Member of the Audit & Supervisory Committee
Name
Takashi Watanabe

3.

Title

Title
Substitute Member of the Audit & Supervisory
Committee <Outside>

Corporate Officers
Name
Fuminori Yoshida
Takaaki Fukushima
Koji Fukushima
Yoshiharu Torikai
Masahiko Okuno (newly appointed)
Hiroyuki Horita (newly appointed)

Title
Corporate Officer, President andChief Executive Officer
Executive Corporate Officer, Chief Financial
Officer
Corporate Officer, Chief Medical Officer
Corporate Officer
Corporate Officer
Corporate Officer (will join on April 1, 2023.)

1

The biographies of the two new corporate officers are as follows:
New Corporate Officer: Masahiko Okuno
CareerApr., 1986
Jun., 1994

Nissan Motor Co., Ltd.
MBA, Harvard University Graduate School of Business
Administration

Jul., 1994Nissan Finance of America, Inc. (Seconded)Jul., 1997

Finance Dept., Nissan Motor Co., Ltd.

Aug., 1998

Consultant, Bain & Company Inc.

Sep., 2001

Novartis Pharma K.K. as Finance Manager

Jan., 2005

Head, Orthopedic and Dermatology Business Unit

Jun., 2005

CFO, Sandoz K.K. (Seconded)Feb., 2008

Manager, Strategic Planning, Novartis Holding (Seconded)Jan., 2009
Jan., 2015
Aug., 2017
Aug., 2021

Head, Marketing & Sales Operations Department, Novartis
Pharma K.K.
Head, Respiratory Business Franchise, Member of Pharma
Executive Committee
Head, Commercial Execution, Member of Pharma ExecutiveCommitteeSenior

Advisor,

Strategic&Commercial

Department

Jun., 2022

Resigned from Novartis Pharma K.K.

Dec., 2022

SymBio, IR Manager and CFO of SPUMar., 2023

Acceleration

Corporate Officer, Head of Corporate Strategy Div. and CFO ofSPU

2

New Corporate Officer: Hiroyuki Horita
CareerApr., 1988

Nippon Chemiphar Co., Ltd.

Nov., 1993

Novo Nordisk Pharma Co., Ltd.

Apr., 2000

Manager, Aichi Iyaku Daiikka, Nagoya BranchJan., 2002

Area Manager, Aichi Area, Chubu BlockJan., 2003

Block Director, Kanto Daini BlockJan., 2007

Sales Director, Norditropin GroupJan., 2009

Block Director, Kanto Daiichi BlockSep., 2014

Board of Director, Head of Sales DivisionJan., 2019

Board of Director, Head of Business Development Division
Sumitomo Dainippon Pharma Co., Ltd., Special Assignment forApr., 2021

Diabetes Area*(* Name change to Sumitomo Pharma on April 1, 2022)

Mar., 2023

Sumitomo Pharma (Planned March 31, 2023)

Apr., 2023

SymBio, Corporate Officer and Sales Division Head (Planned)[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

3